PAS
SWTX

Park Avenue Securities’s SpringWorks Therapeutics SWTX Stock Holding History

Park Avenue Securities’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,867
Closed -$259K – 1565
2025
Q1 		$259K Buy
5,867
+236
+4% +$10.9K ﹤0.01% 1050
2024
Q4 		$203K Buy
+5,631
New +$197K ﹤0.01% 1431

Other funds holding SWTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Park Avenue Securities's SWTX Position: Q2 2025 in Review

Park Avenue Securities sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 5,867 shares — an estimated $259K sold.

Park Avenue Securities first reported a position in SWTX in Q4 2024 and held it in 2 quarters. The position peaked at $259K in Q1 2025. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Park Avenue Securities reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Park Avenue Securities sold 5,867 SpringWorks Therapeutics shares in Q2 2025, an estimated $259K.
  • Park Avenue Securities first reported a position in SpringWorks Therapeutics in Q4 2024 and held it in 2 quarters.
  • Park Avenue Securities's SpringWorks Therapeutics position peaked at $259K in Q1 2025.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Park Avenue Securities's 13F filing for Q2 2025, filed 14 Jul 2025.